Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enclomiphene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 11/20 | 0.97 |
| ▸ | EBP | Q15125 | 6/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.97 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.97 |
| ▸ | MAPT | P10636 | 4/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.97 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.97 |
| ▸ | DRD3 | P35462 | 3/20 | 0.97 |
| ▸ | HTR6 | P50406 | 3/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.97 |
| ▸ | MEN1 | O00255 | 3/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.97 |
| ▸ | HTT | P42858 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zuclomiphene SCHEMBL402392 | 1.00 | ESR1 (0.97) | ESR1EBPKMT2ASIGMAR1CYP2D6 | |
| Clomiphene SCHEMBL27689011 | 1.00 | ESR1 (0.97) | ESR1EBPKMT2ASIGMAR1CYP2D6 | |
| Enclomiphene SCHEMBL34893 | 0.99 | ESR1 (1.00) | ESR1EBPKMT2ASIGMAR1CYP2D6 | |
| Clomiphene SCHEMBL29379763 | 0.99 | ESR1 (1.00) | ESR1EBPKMT2ASIGMAR1CYP2D6 | |
| Enclomiphene SCHEMBL20594021 | 0.99 | ESR1 (1.00) | ESR1EBPKMT2ASIGMAR1CYP2D6 | |
| Zuclomiphene SCHEMBL34894 | 0.99 | ESR1 (1.00) | ESR1EBPKMT2ASIGMAR1CYP2D6 | |
| SCHEMBL10407739 | 0.99 | ESR1 (1.00) | ESR1EBPKMT2ASIGMAR1CYP2D6 | |
| Enclomiphene SCHEMBL5083138 | 0.99 | ESR1 (1.00) | ESR1EBPKMT2ASIGMAR1CYP2D6 | |
| Zuclomiphene SCHEMBL23357662 | 0.94 | ESR1 (0.90) | ESR1EBPKMT2ASIGMAR1CYP2D6 | |
| 4-Oh-Enclomiphene SCHEMBL6768536 | 0.94 | ESR1 (0.90) | ESR1EBPKMT2ASIGMAR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981906-B2 | Trans-clomiphene metabolites and uses thereof | REPROS THERAPEUTICS INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20150265553-A1 | Methods and Materials for the Treatment of Testosterone Deficiency in Men | REPROS THERAPEUTICS INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150202167-A1 | Trans-Clomiphene Formulations and Uses Thereof | REPROS THERAPEUTICS INC. (US) | 2015-07-23 | — | — | US | disclosed |
| US-20140163114-A1 | TRANS-CLOMIPHENE METABOLITES AND USES THEREOF | REPROS THERAPEUTICS INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8247456-B2 | Dosing regimes for trans-clomiphene | REPROS THERAPEUTICS INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120022167-A1 | Trans-Clomiphene for Metabolic Syndrome | REPROS THERAPEUTICS INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20090215907-A1 | DOSING REGIMES FOR TRANS-CLOMIPHENE | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2009-08-27 | — | — | US | disclosed |
| US-7368480-B2 | Methods and compositions with trans-clomiphene | REPROS THERAPEUTICS INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7173064-B2 | Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy | REPROS THERAPEUTICS INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20040171697-A1 | Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy | ZONAGEN, INC. | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163114-A1 | TRANS-CLOMIPHENE METABOLITES AND USES THEREOF | SHBG, CYP19A1, HMGCR | ESR1 111/4885EBP 423/4885KMT2A 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.